Valuation: Alkermes plc

Market Cap 7.76B 6.93B 6.37B 5.78B 10.96B 727B 11.23B 76.23B 30.38B 389B 29.12B 28.5B 1,226B P/E 2026 *
-96.1x
P/E 2027 * 103x
Enterprise Value 8.82B 7.87B 7.24B 6.57B 12.46B 826B 12.77B 86.63B 34.53B 442B 33.09B 32.39B 1,394B EV / Sales 2026 *
4.83x
EV / Sales 2027 * 4.47x
Free-Float
89.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.59%
1 week+2.85%
Current month+1.83%
1 month+13.69%
3 months-6.10%
6 months+31.95%
Current year+65.01%
1 week 44.07
Extreme 44.07
47.07
1 month 38.98
Extreme 38.98
47.43
Current year 27
Extreme 27
55.67
1 year 27
Extreme 27
55.67
3 years 22.06
Extreme 22.06
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 2026-07-31
Director of Finance/CFO 53 2025-09-14
Chief Tech/Sci/R&D Officer 58 2017-05-29
Director TitleAgeSince
Chairman 64 2011-08-31
Director/Board Member 53 2026-07-31
Director/Board Member 74 2016-05-25
Date Insider Type Main position Quantity % Market Cap. Importance
11/3/26 Sell

Compliance Officer

-2,035 0.0012%
10/8/26 Exercice

Chief Financial Officer

22,397 0.0134%
10/7/26 Free

Director

25,237 0.0150%
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%+2.85%+40.38%+88.37% 7.76B
+4.28%+0.07%+52.75%+138.78% 1,258B
+2.13%+4.27%+51.21%+91.36% 679B
+0.68%+1.54%+33.83%+112.47% 518B
+0.11%+2.66%+43.92%+69.55% 390B
+1.38%+0.27%+72.42%+45.30% 367B
+0.46%+1.98%+31.21%+59.91% 307B
-0.07%+2.09%+7.02%+39.23% 293B
+1.04%-0.05%+45.29%+76.18% 252B
+1.46%-0.59%+42.48%+125.82% 210B
Average +0.61%+1.23%+42.05%+84.70% 428B
Weighted average by Cap. +0.59%+1.18%+45.46%+96.89%

Financials

2026 *2027 *
Net sales 1.82B 1.63B 1.5B 1.36B 2.58B 171B 2.64B 17.92B 7.14B 91.54B 6.85B 6.7B 288B 1.92B 1.72B 1.58B 1.43B 2.72B 180B 2.79B 18.91B 7.54B 96.57B 7.22B 7.07B 304B
Net income -84.46M -75.39M -69.37M -62.96M -119M -7.92B -122M -830M -331M -4.24B -317M -310M -13.35B 79.36M 70.84M 65.18M 59.16M 112M 7.44B 115M 780M 311M 3.98B 298M 291M 12.54B
Net Debt 1.06B 945M 869M 789M 1.5B 99.2B 1.53B 10.4B 4.14B 53.11B 3.97B 3.89B 167B 840M 750M 690M 626M 1.19B 78.77B 1.22B 8.26B 3.29B 42.17B 3.15B 3.09B 133B
Projected Income Statement - Annual - Alkermes plc
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
26-11-09 US$46.17 +0.59% 1,709,146
26-11-06 US$45.90 +3.05% 1,673,442
26-11-05 US$44.54 -2.94% 1,943,983
26-11-04 US$45.89 +0.44% 2,179,091
26-11-03 US$45.69 +1.78% 2,328,628
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Alkermes plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
46.17USD
Average target price
57.74USD
Spread / Average Target
+25.05%
  1. Stock Market
  2. Stocks
  3. ALKS Stock